[go: up one dir, main page]

TW200738266A - Pharmaceutical agent containing insulin resistance improving agent - Google Patents

Pharmaceutical agent containing insulin resistance improving agent

Info

Publication number
TW200738266A
TW200738266A TW095135757A TW95135757A TW200738266A TW 200738266 A TW200738266 A TW 200738266A TW 095135757 A TW095135757 A TW 095135757A TW 95135757 A TW95135757 A TW 95135757A TW 200738266 A TW200738266 A TW 200738266A
Authority
TW
Taiwan
Prior art keywords
insulin resistance
resistance improving
containing insulin
agent
agent containing
Prior art date
Application number
TW095135757A
Other languages
English (en)
Inventor
Shoichi Kanda
Ryutaro Nakashima
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200738266A publication Critical patent/TW200738266A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095135757A 2005-09-29 2006-09-27 Pharmaceutical agent containing insulin resistance improving agent TW200738266A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005283466 2005-09-29

Publications (1)

Publication Number Publication Date
TW200738266A true TW200738266A (en) 2007-10-16

Family

ID=37899720

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095135757A TW200738266A (en) 2005-09-29 2006-09-27 Pharmaceutical agent containing insulin resistance improving agent

Country Status (6)

Country Link
US (1) US20090124626A1 (zh)
EP (1) EP1935432A1 (zh)
JP (1) JPWO2007037296A1 (zh)
CN (1) CN101277719A (zh)
TW (1) TW200738266A (zh)
WO (1) WO2007037296A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820666B2 (en) 2007-05-08 2010-10-26 Concert Pharmaceuticals, Inc. Tetrahydrotriazolopyrazine derivatives and uses thereof
CN101849944A (zh) * 2009-03-31 2010-10-06 江苏恒瑞医药股份有限公司 治疗2型糖尿病的药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
ES2487897T3 (es) * 2000-01-21 2014-08-25 Novartis Ag Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP2001315032A (ja) * 2000-05-08 2001-11-13 Mori Seiki Co Ltd 工作機械
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) * 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
CA2564884A1 (en) * 2004-05-18 2005-12-08 Merck & Co., Inc. Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US8017633B2 (en) * 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus

Also Published As

Publication number Publication date
EP1935432A1 (en) 2008-06-25
WO2007037296A1 (ja) 2007-04-05
CN101277719A (zh) 2008-10-01
JPWO2007037296A1 (ja) 2009-04-09
US20090124626A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
SI3326673T1 (sl) Brizge, vmesniki brizg in bati brizge za uporabo z medicinskimi injektorji
WO2007146426A3 (en) Nanoshells for drug delivery
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
UA87334C2 (ru) Приводной механизм для применения в устройстве введения лекарств, устройство введения лекарств, применение приводного механизма (варианты) и способ сборки устройства введения лекарств
TW200745037A (en) Organic compounds
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
EP1611880A3 (en) Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction
WO2010049678A3 (en) Treatment of energy utilization diseases
MX2011008416A (es) Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2006053043A3 (en) Methods of treating diabetes mellitus
WO2007079171A3 (en) Treatment for hodgkin's lymphoma
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
EP1948273A4 (en) SYRINGE GUARD FOR PRE-FILLED MEDICINAL FLASK
EP1561472A4 (en) SOLID PREPARATION
MY152172A (en) Therapeutic agent for diabetes
TN2009000119A1 (en) Combination drug
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
TW200806293A (en) Methods of treatment with CETP inhibitors
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
TW200738266A (en) Pharmaceutical agent containing insulin resistance improving agent
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
IL171911A0 (en) Catheter for uniform delivery of medication
TW200633720A (en) Medicinal composition for diabetic